

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-21 (canceled)

Claim 22 (new): A compound selected from the group consisting of:
4-amino-7-(2-*C*-methyl- β -D-arabinofuranosyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine, 5'-mono- or diphosphate;
4-amino-7-(2-*C*-methyl- β -D-ribofuranosyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine, 5'-mono- or diphosphate;
4-amino-7-(2-*C*-fluoromethyl- β -D-ribofuranosyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine, 5'-mono- or diphosphate;
4-amino-5-methyl-7-(2-*C*-methyl- β -D-ribofuranosyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine, 5'-mono- or diphosphate;
4-amino-5-bromo-7-(2-*C*-methyl- β -D-ribofuranosyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine, 5'-mono- or diphosphate;
4-amino-5-chloro-7-(2-*C*-methyl- β -D-ribofuranosyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine, 5'-mono- or diphosphate;
4-amino-5-fluoro-7-(2-*C*-methyl- β -D-ribofuranosyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine, 5'-mono- or diphosphate;
2-amino-7-(2-*C*-methyl- β -D-ribofuranosyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4(3*H*)-one, 5'-mono- or diphosphate; and
4-amino-7-(2-*C*,2-*O*-dimethyl- β -D-ribofuranosyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine, 5'-mono- or diphosphate;
or a pharmaceutically acceptable salt thereof.


Claim 23 (new): The compound of Claim 22 which is
4-amino-7-(2-*C*-methyl- β -D-ribofuranosyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine, 5'-mono- or diphosphate; or
a pharmaceutically acceptable salt thereof.

Claim 24 (new): The compound of Claim 22 which is
4-amino-7-(2-*C*-fluoromethyl- β -D-ribofuranosyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine, 5'-mono- or diphosphate; or a pharmaceutically acceptable salt thereof.

Claim 25 (new): The compound of Claim 22 which is 2-amino-7-(2-*C*-methyl- β -D-ribofuranosyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4(3*H*)-one, 5'-mono- and diphosphate; or a pharmaceutically acceptable salt thereof.

Claim 26 (new): The compound of Claim 22 which is 4-amino-5-fluoro-7-(2-*C*-methyl- β -D-ribofuranosyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine, 5'-mono- and diphosphate; or a pharmaceutically acceptable salt thereof.

Claim 27 (new): A method of treating a *Flaviviridae* virus infection or a *Picorniviridae* virus infection comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of the structural formula:



or a pharmaceutically acceptable salt thereof;

wherein R^a and R^h are each independently selected from the group consisting of hydrogen, cyano, azido, halogen, hydroxy, mercapto, amino, C₁₋₄ alkoxy, C₂₋₄ alkenyl, C₂₋₄ alkynyl, and C₁₋₄ alkyl, wherein alkyl is unsubstituted or substituted with hydroxy, amino, C₁₋₄ alkoxy, C₁₋₄ alkylthio, or one to three fluorine atoms;

R^b is C₂₋₄ alkenyl, C₂₋₄ alkynyl, or C₁₋₄ alkyl, wherein alkyl is unsubstituted or substituted with hydroxy, amino, C₁₋₄ alkoxy, C₁₋₄ alkylthio, or one to three fluorine atoms;

R^c is hydrogen, fluorine, hydroxy, mercapto, C₁₋₄ alkoxy, or C₁₋₄ alkyl; or R^b and R^c together with the carbon atom to which they are attached form a 3- to 6-membered saturated monocyclic ring system optionally containing a heteroatom selected from O, S, and NC₀₋₄ alkyl;

R^d is hydrogen, cyano, nitro, C₁₋₃ alkyl, NHCONH₂, CONR₁R₂, CSNR₁R₂, COOR₁, C(=NH)NH₂, hydroxy, C₁₋₃ alkoxy, amino, C₁₋₄ alkylamino, di(C₁₋₄ alkyl)amino, halogen, (1,3-oxazol-2-yl), (1,3-thiazol-2-yl), or (imidazol-2-yl); wherein alkyl is unsubstituted or substituted with one to three groups independently selected from halogen, amino, hydroxy, carboxy, and C₁₋₃ alkoxy;

R^e and R^f are each independently hydrogen, hydroxy, halogen, C₁₋₄ alkoxy, amino, C₁₋₄ alkylamino, di(C₁₋₄ alkyl)amino, C₃₋₆ cycloalkylamino, di(C₃₋₆ cycloalkyl)amino, or C₄₋₆ cycloheteroalkyl,

unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, amino, C₁₋₄ alkyl, and

C₁₋₄ alkoxy;

R_g is hydrogen, C₁₋₄ alkyl, C₂₋₄ alkynyl, halogen, cyano, carboxy, C₁₋₄ alkyloxycarbonyl, azido, amino, C₁₋₄ alkylamino, di(C₁₋₄ alkyl)amino, hydroxy,

C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkylsulfonyl, (C₁₋₄ alkyl)₀₋₂ aminomethyl, or


C₄₋₆ cycloheteroalkyl, unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, amino, C₁₋₄ alkyl, and C₁₋₄ alkoxy;

Rⁱ is hydrogen, C₁₋₁₀ alkylcarbonyl, P₃O₉H₄, P₂O₆H₃, or P(O)R^mRⁿ;

each R_j is independently hydrogen or C₁₋₆ alkyl;

R^k and R^l are each independently hydrogen, methyl, hydroxymethyl, or fluoromethyl; and

R^m and Rⁿ are each independently hydroxy, OCH₂CH₂SC(=O)C₁₋₄ alkyl, OCH₂O(C=O)OC₁₋₄ alkyl, NHCHMeCO₂Me, OCH(C₁₋₄ alkyl)O(C=O)C₁₋₄ alkyl,



Claim 28 (new): The method of Claim 27 wherein said *Flaviviridae* virus infection is rhinovirus infection or poliovirus infection.

Claim 29 (new): The method of Claim 27 wherein said *Picorniviridae* virus infection is selected from the group consisting of yellow fever virus infection, dengue virus infection, West Nile virus infection, Japanese encephalitis virus infection, Banzi virus infection, and bovine viral diarrhea virus infection.

Claim 30 (new): A method of treating hepatitis C virus (HCV) infection comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 27 in combination with a therapeutically effective amount of another agent active against HCV selected from the group consisting of ribavirin; levovirin; thymosin alpha-1; an inhibitor of NS3 serine protease; an inhibitor of inosine monophosphate dehydrogenase; and interferon- α or pegylated interferon- α , alone or in combination with ribavirin or levovirin.

Claim 31 (new): The method of Claim 30 wherein said agent active against HCV is interferon- α or pegylated interferon- α , alone or in combination with ribavirin or levovirin.